Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04476030 · ClinicalTrials.gov registry record · Phase 3
A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder
A Phase 3 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 3
- Development phase
- 440
- Enrollment target
NCT04476030 is a Phase 3 study that has completed, run by Biogen. The registered enrollment target is 440 participants.
The verdict
NCT04476030, a Phase 3 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 440 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the efficacy of SAGE-217 plus an ADT in the treatment of major depressive disorder (MDD) compared to placebo plus an ADT.
Interventions
- DRUG Escitalopram
- DRUG Matching Placebo
- DRUG Sertraline
- DRUG Citalopram
- DRUG SAGE-217
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 440 participants |
| Start Date | 2020-11-09 |
| Est. Completion | 2021-12-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04476030
The ClinicalTrials.gov registry entry for NCT04476030 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 440 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Escitalopram is the first listed.
NCT04476030 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04476030 about?
NCT04476030 is a clinical study titled "A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder". The primary purpose of this study is to evaluate the efficacy of SAGE-217 plus an ADT in the treatment of major depressive disorder (MDD) compared to placebo plus an ADT.
What is the current status of trial NCT04476030?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 440 participants. The study started on 2020-11-09. Estimated completion is 2021-12-22.
What interventions are being tested in trial NCT04476030?
The interventions under investigation include: Escitalopram (DRUG), Matching Placebo (DRUG), Sertraline (DRUG), Citalopram (DRUG), SAGE-217 (DRUG).
Who is sponsoring clinical trial NCT04476030?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.